Articles from Anumana

Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the studies highlighted was a late-breaking featured science presentation, published simultaneously in the Journal of the American College of Cardiology, showing that AI applied to the electrocardiogram (ECG-AI) can enhance near-term prediction of incident heart failure beyond established clinical risk models. Anumana also has three additional abstracts being presented at the meeting.

Anumana, a leader in AI-powered cardiovascular diagnostics, will present groundbreaking clinical studies demonstrating how AI applied to electrocardiograms (ECG) can uncover early signs of heart disease and inform clinical care. The company’s late-breaking featured science study, along with three additional accepted abstracts, will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7–10 in New Orleans, LA. Anumana will also host several interactive experiences for attendees to explore how AI can be seamlessly integrated into cardiovascular care.

Anumana, a leading AI-driven health technology company, has expanded beyond its diagnostic ECG-AI™ technology into perioperative and acute cardiac care. The company recently brought on Boston Scientific Corporation as a new investor in its Series C financing round, accelerating the development of a multimodal generative AI platform and Software as a Medical Device (SaMD) while advancing Anumana’s leadership in AI-powered cardiovascular diagnostics.

Anumana, a leading AI-driven health technology company, announced the appointment of Dr. Simos Kedikoglou as President and Chief Operating Officer (COO), effective immediately.

Anumana, a leading AI-driven health technology company, today announced a collaboration with AliveCor to develop Anumana’s advanced AI algorithms for early cardiac disease detection on AliveCor’s Kardia electrocardiogram (ECG) devices, starting with Anumana’s FDA-cleared algorithm, ECG-AI™ LEF.

Anumana, a leading AI-driven health technology company, announced a new collaboration with the American College of Cardiology to join its Innovation Program and accelerate the detection and treatment of cardiovascular disease.

Anumana, a leading AI-driven health technology company, has been named to Fast Company’s 2024 Next Big Things in Tech list in the Health category. This distinction highlights Anumana’s work leveraging artificial intelligence (AI) to transform routine electrocardiograms (ECG) into tools that enable earlier diagnosis and treatment.

Anumana, a leading AI-driven health technology company, will showcase its leadership in AI-powered cardiovascular solutions at the American Heart Association (AHA) Scientific Sessions 2024, booth #708, in Chicago, and at the North American Primary Care Research Group (NAPCRG) Annual Meeting in Quebec City.

Anumana, a leading artificial intelligence (AI)-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has included its low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval allows outpatient settings to receive reimbursement for using Anumana’s ECG-AI service to help identify LEF in adults at risk for heart failure, aiding early detection of cardiac dysfunction.

Anumana, a leading AI-driven health technology company and portfolio company of nference, has joined the Accelerating Medicines Partnership® (AMP®) Heart Failure program. Managed by the Foundation of the National Institutes of Health (FNIH), this initiative brings together leaders in academia, industry, and government to advance critical research and improve outcomes for patients.

Anumana, a leading AI-driven health technology company and portfolio company of nference, announced a new study that revealed promising results in support of further development of its investigational pulmonary hypertension (PH) algorithm. The study, “An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension,” which was published in the European Respiratory Journal, determined that the algorithm used in the study can detect PH using routine 12-lead electrocardiogram (ECG) data.

Anumana, a leading AI-driven health technology company and portfolio company of nference, and InfoBionic.Ai, a digital health company specializing in remote cardiac monitoring and diagnostic solutions, today announced a joint research collaboration agreement to develop and commercialize the next generation of remote cardiac care solutions, combining Anumana’s breakthrough ECG-AI™ technology and InfoBionic.Ai’s MoMe ARC® platform.

Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today that it has received the International Organization for Standardization (ISO) 13485 certification for its Quality Management System. This certification, the quality management standard for device manufacturers, indicates that a company has developed robust policies and procedures for the development and manufacture of regulated medical devices.

Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry S. Palmin as chief financial officer (CFO). As a veteran in building, financing, and operating life sciences companies, Palmin brings over 25 years of experience to Anumana’s executive leadership team. In his new role, he will lead financial operations, investor relations, and corporate development activities at Anumana, and guide the company’s strategic growth. In addition to his role as CFO of Anumana, Palmin joins nference as CFO, Ventures.

Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors. Murali Aravamudan, co-founder of Anumana and nference, has transitioned to executive chairman of the Anumana Board of Directors while continuing as CEO of nference. Nanavaty will lead Anumana through a period of growth as the company begins deploying and commercializing its multi-indication ECG-AI platform technology.

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has been named one of Fierce Medtech’s 2022 Fierce 15. This prestigious honor indicates that the two-year-old company is well-positioned to transform cardiac care by leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart.

Anumana, an AI-driven health technology company and portfolio company of nference, announced today it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP). The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.